GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (STU:PF42) » Definitions » Cyclically Adjusted FCF per Share

Interpace Biosciences (STU:PF42) Cyclically Adjusted FCF per Share : €-41.57 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Interpace Biosciences Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Interpace Biosciences's adjusted free cash flow per share for the three months ended in Mar. 2024 was €-0.018. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-41.57 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 1.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -1.70% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -19.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Interpace Biosciences was 38.60% per year. The lowest was -269.80% per year. And the median was -3.55% per year.

As of today (2024-06-07), Interpace Biosciences's current stock price is €1.23. Interpace Biosciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €-41.57. Interpace Biosciences's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Interpace Biosciences was 42.79. The lowest was 10.38. And the median was 12.91.


Interpace Biosciences Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Interpace Biosciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Interpace Biosciences Cyclically Adjusted FCF per Share Chart

Interpace Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -36.24 -44.09 -51.78 -32.35 -44.71

Interpace Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -48.02 -44.98 - -44.71 -41.57

Competitive Comparison of Interpace Biosciences's Cyclically Adjusted FCF per Share

For the Diagnostics & Research subindustry, Interpace Biosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Interpace Biosciences's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Interpace Biosciences's Cyclically Adjusted Price-to-FCF falls into.



Interpace Biosciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Interpace Biosciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.018/131.7762*131.7762
=-0.018

Current CPI (Mar. 2024) = 131.7762.

Interpace Biosciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -10.725 100.560 -14.054
201409 -44.872 100.428 -58.879
201412 -54.235 99.070 -72.140
201503 -37.460 99.621 -49.551
201506 -15.243 100.684 -19.950
201509 -30.860 100.392 -40.508
201512 -34.863 99.792 -46.037
201603 -20.028 100.470 -26.269
201606 -6.363 101.688 -8.246
201609 -6.588 101.861 -8.523
201612 -5.048 101.863 -6.530
201703 -8.856 102.862 -11.345
201706 -4.075 103.349 -5.196
201709 -1.642 104.136 -2.078
201712 -0.722 104.011 -0.915
201803 -0.744 105.290 -0.931
201806 -0.782 106.317 -0.969
201809 -0.632 106.507 -0.782
201812 -0.594 105.998 -0.738
201903 -0.749 107.251 -0.920
201906 -1.128 108.070 -1.375
201909 -1.148 108.329 -1.396
201912 -1.509 108.420 -1.834
202003 -1.610 108.902 -1.948
202006 0.099 108.767 0.120
202009 -1.203 109.815 -1.444
202012 -0.322 109.897 -0.386
202103 -1.028 111.754 -1.212
202106 -0.368 114.631 -0.423
202109 -0.138 115.734 -0.157
202112 -0.258 117.630 -0.289
202203 -0.275 121.301 -0.299
202206 -0.668 125.017 -0.704
202209 -0.782 125.227 -0.823
202212 -0.104 125.222 -0.109
202303 0.231 127.348 0.239
202306 0.064 128.729 0.066
202309 0.000 129.860 0.000
202312 0.208 129.419 0.212
202403 -0.018 131.776 -0.018

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Interpace Biosciences  (STU:PF42) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Interpace Biosciences was 42.79. The lowest was 10.38. And the median was 12.91.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Interpace Biosciences Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Interpace Biosciences's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Interpace Biosciences (STU:PF42) Business Description

Traded in Other Exchanges
Address
300 Interpace Parkway, Morris Corporate Center 1, Building C, Parsippany, NJ, USA, 07054
Interpace Biosciences Inc is engaged in the life sciences industry. It provides molecular diagnostics, bioinformatics, and pathology services for the evaluation of the risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first-line assays principally focused on the early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. It operates under one segment which is the business of developing and selling diagnostic clinical services.

Interpace Biosciences (STU:PF42) Headlines

No Headlines